All main goals hit in trial testing AlphaMedix for pancreatic cancer
A Phase 2 clinical trial testing Sanofi‘s therapy candidate AlphaMedix (212Pb-DOTAMTATE) in people with a certain type of pancreatic cancer has hit all its…
Pancreatic cancer
Utidelone now FDA orphan drug after promising cancer trial results
Biostar Pharma’s experimental therapy utidelone has been granted orphan drug status for pancreatic cancer by the U.S. Food and Drug Administration (FDA). The…
Atebimetinib yields ‘extraordinary’ results in pancreatic cancer trial
An experimental cancer therapy known as atebimetinib is delivering “extraordinary” results for patients with pancreatic cancer. New data from an ongoing Phase 2a clinical…
New blood test detects multiple cancers at early stages
A new blood test capable of detecting multiple cancers at earlier, more treatable stages is now available in the U.S. for $689, its developer said.
Rapid spread of rare pancreatic cancer to liver detailed in report
A rapidly growing pancreatic signet ring cell adenocarcinoma, a rare and aggressive type of pancreatic cancer, was reported to have spread to the liver…
Chemical in cigarette smoke drives pancreatic cancer: Study
A chemical in cigarette smoke can increase the odds of developing pancreatic cancer by changing the immune system’s activity. That’s according to a new…
Novocure files for FDA approval of TTFields for pancreatic cancer
Novocure has filed an application asking the U.S. Food and Drug Administration to approve its Tumor Treating Fields (TTFields) therapy for treating locally advanced…
KRAS-mutated pancreatic cancer vaccine triggers immune response
A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people…
Committee recommends study of pancreatic cancer vaccine continue
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
Early results ‘extremely positive’ for pancreatic cancer treatment combo
A clinical trial has revealed encouraging results for people with metastatic pancreatic cancer who received Ampligen (rintatolimod) alongside Imfinzi (durvalumab). Nearly two-thirds of…
